frequently asked questions

Company


When was Turing Pharmaceuticals founded?

Turing Pharmaceuticals began commercial operations as a privately-funded, research-based pharmaceutical company in February 2015.

  • The new company announced its focus on developing and commercializing innovative treatments for serious diseases for which there are limited or no treatment options.

Who owns the company?

Turing is privately-held, which means the company is owned by a group of private investors. Turing is not listed on the stock market and shares are not publicly traded.

In December 2015 Ron Tilles was named CEO.

Where does the company operate?

Turing Pharmaceuticals AG is a privately-held biopharmaceutical company with offices in Zug, Switzerland, and New York, NY. The company markets its products in the United States.

How many people work for the company?

Approximately 100 (August 2016).

The two largest functions are Commercial and Research & Development.

  • Commercial includes:
    • Our Sales team - account managers, who work with hospitals and healthcare providers to share knowledge about our medicines)
    • A national Alliance Development team that offers unbranded, non-promotional disease awareness programs to case managers, nurses and other non-prescribers.
  • R&D includes:
    • Discovery
    • Regulatory Affairs & Quality
    • Clinical Research
    • Chemistry Manufacturing & Controls
    • Medical Affairs.
  • Other colleagues work in Business Development, and various essential support functions.

What products does the company sell?

DARAPRIM


What is the price of Daraprim®?

The Wholesale Acquisition Cost (WAC) is $750 per pill, which is consistent with industry practices for medications used to treat rare diseases. There is, however, no single price.

  • Approximately two thirds of DARAPRIM sales are to Federal and State health programs that pay Turing just 1 cent per pill ($1 per 100-tablet bottle) net after discount. The majority of these discounted sales goes to our 340B customers.
  • Turing offers DARAPRIM to the Department of Veterans Affairs and Department of Defense at a heavily discounted price.

There are several financial assistance programs available1.

  • Turing funds a patient assistance program that offers DARAPRIM free of charge to qualified, uninsured patients with incomes at or below 500 percent of the federal poverty level.
  • Eligible patients who have commercial insurance may receive cost sharing support and are not obligated to pay more than $10 out of pocket for DARAPRIM.
  • Eligible patients with Medicare Part D insurance coverage have access to an independent charitable foundation, to which Turing donates, to assist with affordability of disease treatment.

1Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuance without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance.

How was the price calculated?

Like other research-based pharmaceutical companies, Turing relies on today's income to fund the search for tomorrow's scientific and medical advancements. Turing's price structure takes into account the challenges and complexities of this unique market. These include:

  • The medicine's clinical value
  • The very small number of patients in the United States diagnosed and treated.
  • Mandatory discounts to Federal and State programs
    • Approximately two thirds of this total access their medicine through state and federal health programs that pay Turing 1¢ per pill ($1 per 100-pill bottle), net after discount. The company receives no other income from these sales.
  • The need to help disadvantaged patients access their medicines
    • Turing funds access support programs1. Eligible patients receive DARAPRIM free of charge, or pay greatly reduced out-of-pocket charges.
  • The company's determination to invest in the discovery and development of improved therapies for toxoplasmosis and other serious and forgotten diseases.
    • In 2015, Turing reinvested 60 percent of net revenue (income minus business expenses) in Research & Development.
    • Turing's Discovery program aims to identify novel drug candidates that may be more potent and may be better tolerated than existing therapies. Several compounds are now being tested.

1Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuance without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance.

Why is Turing the sole US supplier of this branded medicine?

In August 2015, Turing purchased the sole rights to manufacture and sell DARAPRIM in the United States including Puerto Rico.

Like all prescription medicines sold in the United States, DARAPRIM is approved by the Food and Drug Administration. The FDA protects public health by monitoring quality, safety and efficacy. It also regulates promotion and other medical and commercial activities.

The FDA can approve a generic competitor if it is shown to have the same dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.

To date, there has been no generic approval.

Why is Daraprim® not dispensed through retail pharmacies?

DARAPRIM treats a rare disease. This small number of dispensed prescriptions presents significant distribution challenges that Turing beleives are best addressed through Specialty distribution channels.

Turing aims to ensure that all prescribers have prompt access to DARAPRIM tablets for their patients. Since acquiring the medicine, Turing has worked with pharmacies, AIDS Drug Assistance Programs and others to simplify communications, overcome pre-existing distribution challenges and help ensure timely delivery.

What happens if a patient cannot afford Daraprim®?

Turing aims to ensure that no patient needing DARAPRIM will be denied access.

The company created the website DARAPRIM Direct to help make the process of obtaining the medicine as simple and easy as possible. Healthcare professionals and patients can speak to a live support team, who assist with DARAPRIM delivery, reimbursement and financial assistance, and other services.

  • Turing funds a patient assistance program1 that offers DARAPRIM free of charge to qualified, uninsured patients with incomes at or below 500 percent of the federal poverty level.
  • Eligible patients who have commercial insurance may receive cost sharing support and are not obligated to pay more than $10 out of pocket for DARAPRIM.
  • Eligible patients with Medicare Part D insurance coverage have access to an independent charitable foundation, to which Turing donates, to assist with affordability of disease treatment.

1Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuance without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance.

Research & Development


How much does Turing invest in R&D?

Turing is a research-based company that is committed to innovation. In 2015, it reinvested 60 per cent of its net revenue (incoming minus business expenses) into research and development.

Where is the company's R&D conducted?

Turing is determined to find new, better, faster ways to conduct R&D in serious and neglected diseases. In its first year, the company found the means to quickly build an R&D infrastructure.

Turing's President R&D and his management team are based at the company's headquarters in New York, NY. From there, they manage research in USA and other countries. This is conducted at contract research organizations and in partnership with academic institutions.

What disease states are under investigation?

Turing has an agile, pragmatic approach to R&D, and constantly seeks new opportunities to contribute scientific knowledge in serious and neglected diseases. At present, the company has active development programs in toxoplasmosis.

What other R&D activities are underway?

While there is certainly need for novel molecules, Turing recognizes that existing toxoplasmosis therapies might be further developed. Scientific programs are underway to explore alternative pyrimethamine formulations intended to better meet the specific needs of distinct patient populations.

Turing is also building knowledge on how toxoplasmosis is treated in the US and in other countries where incidence is far higher. In some areas of Brazil, for example, ocular toxoplasmosis is remarkably common.

The lack of significant industry innovation in toxoplasmosis in the decades following the introduction of existing therapies has resulted in an absence of pharmacological advancement. Turing is working to address this gap and add to scientific knowledge about toxoplasmosis therapy. These efforts include health economics (true cost of treatment), disease biology and other areas of research. Turing aims to share these data, in detail, with the scientific community in due course.

You are about to enter a site that is for US healthcare professionals only. By clicking “Confirm” below, you certify that you are a healthcare professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.

I am a licensed healthcare professional and wish to proceed to the Healthcare Professionals section of this site.